 |
|
 |
|
| |
Noncoding RNAs:
A New Paradigm for Gene Regulation
Event Date: October 22, 2008 12:00 Noon Eastern Time; 9:00 a.m. Pacific Time, 4 p.m. GMT
Brought to you by the Science/AAAS Business Office
|
|
| |
Real Player | | | Real Media Video (56k/150k) | | |
Windows Media Player | | | Windows Media Video (56k/150k) |
|
| |
|
|
| |
Non-coding RNAs (ncRNAs) are a large group of RNAs that are transcribed, but not translated into protein. They include well-characterized transfer RNAs and ribosomal RNAs, as well as newer and more elusive miRNAs which have been shown to play a crucial role in gene regulation. ncRNAs produce functional RNA molecules rather than encoding proteins and have been found to have roles in a plethora of cellular processes including transcriptional regulation, RNA processing and modification, mRNA stability, and even protein degradation. Even though a large number of genomes have been sequenced, the number and diversity of ncRNA-encoding genes is largely unknown.
Many more ncRNAs have been discovered than were predicted, with recent transcriptomic and microarray studies suggesting that, for the mouse genome alone, there exists more than 30,000 long ncRNAs. The challenge now facing researchers is to determine the size of the full compliment of ncRNAs, as well as elucidate their function, particularly in disease. This online discussion will center on the different forms of ncRNAs, and the roles they may play in the biology and pathology of human disease.
During this webinar, the expert panel will:
- Provide a general introduction to the different types of non-coding RNAs
- Discuss how technologies for detecting and characterizing ncRNAs can be applied in disease research
- Share data on recent ncRNA studies
- Answer your questions live!
|
|
| |
Speakers:
 |
George Calin, M. D., Ph.D.
Anderson Cancer Center
Houston, Texas
George Adrian Calin received both his M.D. and Ph.D. degrees at Carol Davila University of Medicine in Bucharest, Romania. After working cytogenetics as undergraduate student with Dragos Stefanescu in Bucharest, he completed his cancer genomics training in Massimo Negrini’s laboratory at University of Ferrara, Italy. In 2000 he became a postdoctoral fellow at Kimmel Cancer Center in Philadelphia, PA, in Carlo Croce’s laboratory. He is presently an Associate Professor in Experimental Therapeutics at MD Anderson Cancer Center and studies the roles of microRNAs and other noncoding RNAs in cancer initiation and progression, as well as the mechanisms of cancer predisposition, and explores new RNA therapeutic options for cancer patients.
|
 |
Joshua Mendell
Institute of Genetic Medicine
Johns Hopkins University
Baltimore, MD
Dr. Joshua Mendell completed his undergraduate education with honors in Biology at Cornell University in 1996. He then joined the Medical Scientist Training Program at the Johns Hopkins University School of Medicine and was awarded an M.D.-Ph.D. degree in 2003. During his doctoral and postdoctoral training, Dr. Mendell studied nonsense-mediated mRNA decay (NMD), making important contributions to this field including the identification and functional characterization of core mammalian components of the NMD pathway. After starting his independent research group at Johns Hopkins in 2004, Dr. Mendell switched his focus to the study of microRNA (miRNA) regulation and function in normal physiology and disease. His laboratory provided one of the earliest demonstrations that miRNAs are functional components of critical oncogenic and tumor suppressor pathways. The Mendell laboratory has also characterized novel mechanisms of miRNA regulation. Dr. Mendell has been the recipient of several prestigious awards including being named a Rita Allen Foundation and Leukemia and Lymphoma Foundation Scholar. He was named the Outstanding Young Scientist in the State of Maryland by the Maryland Academy of Sciences in 2007.
|
|
|
| |
Moderator: Sean Sanders, Ph.D., Commercial Editor, Science/AAAS
 |
Sean Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. under Sir Dillwyn Williams at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor in 2004 before recently taking the position of Commercial Editor at Science/AAAS.
|
|
|
|
| |
___________________________________________________________________________________________________
|
 |
|
| |
For the best experience we recommend you use Internet Explorer 6 (IE6) or higher on a Windows-based PC to view this webinar. Please ensure that you are using a computer with a stable internet connection and good bandwidth. To ensure the best possible performance of the webinar we recommend that you avoid using a dial-up connection. Note: please confirm the start time of the webinar in your time zone. A free time zone converter is available at www.timeanddate.com/worldclock/converter.html
|
| |
Test Your System
|
| | Help |
| |
Download Real Player
|
| |
Download Windows Media Player
|
| |
|
|
|